Literature DB >> 15307581

Reactivation of tuberculosis during immunosuppressive treatment in a patient with a positive QuantiFERON-RD1 test.

Pernille Ravn1, Martin E Munk, Ase Bengaard Andersen, Bettina Lundgren, Lars N Nielsen, Troels Lillebaek, Inge J Soerensen, Peter Andersen, Karin Weldingh.   

Abstract

A patient with polymyositis developed tuberculosis during immunosuppressive treatment. Tuberculin Skin Test and chest X-ray failed to demonstrate latent tuberculosis, whereas a blood sample that was tested with a modified QuantiFERON-TB-assay, using the recombinant ESAT-6 and CFP-10, was positive indicating that this patient was latently infected before immunosuppressive therapy. This case indicates the risk of progressing from latent to active tuberculosis given that the subject is RD1 responsive, and we believe that preventive anti-tuberculous treatment could have prevented this case of tuberculosis. We suggest that RD1 based tests are evaluated further in immunocompromised patients.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15307581     DOI： 10.1080/00365540410015222

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN： 0036-5548


  10 in total

1.  High association of mycobacterial infections with polymyositis in a non-endemic country for tuberculosis.

Authors:  Antti Airio; Markku Kauppi; Hannu Kautiainen; Markku Hakala; Vuokko Kinnula
Journal:  Ann Rheum Dis       Date:  2007-10       Impact factor: 19.103

2.  Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis.

Authors:  Pernille Ravn; Martin E Munk; Ase B Andersen; Bettina Lundgren; Jens D Lundgren; Lars N Nielsen; Axel Kok-Jensen; Peter Andersen; Karin Weldingh
Journal:  Clin Diagn Lab Immunol       Date:  2005-04

Review 3.  Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases.

Authors:  R John Looney; Betty Diamond; V Michael Holers; Marc C Levesque; Larry Moreland; Moon H Nahm; E William St Clair
Journal:  Clin Immunol       Date:  2007-02-27       Impact factor: 3.969

4.  Infections and the relationship to treatment in neuromuscular autoimmunity.

Authors:  Devin E Prior; Emily Nurre; Stephanie L Roller; David Kline; Ramit Panara; Amro M Stino; John A Davis; Miriam L Freimer; W David Arnold
Journal:  Muscle Nerve       Date:  2017-12-20       Impact factor: 3.217

5.  Rhinofacial Conidiobolus coronatus infection presenting with nasal enlargement.

Authors:  N Fischer; Ch Ruef; C Ebnöther; E B Bächli
Journal:  Infection       Date:  2008-11-08       Impact factor: 3.553

6.  Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy.

Authors:  Jérémie Sellam; Haifa Hamdi; Carine Roy; Gabriel Baron; Marc Lemann; Xavier Puéchal; Maxime Breban; Francis Berenbaum; Marc Humbert; Karin Weldingh; Dominique Salmon; Philippe Ravaud; Dominique Emilie; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2007-04-24       Impact factor: 19.103

7.  Evaluation of interferon-gamma release assays for the diagnosis of tuberculosis: an updated meta-analysis.

Authors:  Y Dai; Y Feng; R Xu; W Xu; W Lu; J Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-26       Impact factor: 3.267

8.  Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis.

Authors:  R Phillips; C Horsfield; S Kuijper; S F Sarfo; J Obeng-Baah; S Etuaful; B Nyamekye; P Awuah; K M Nyarko; F Osei-Sarpong; S Lucas; A H J Kolk; M Wansbrough-Jones
Journal:  Clin Vaccine Immunol       Date:  2006-02

9.  Rapid diagnosis of CNS tuberculosis by a T-cell interferon-gamma release assay on cerebrospinal fluid mononuclear cells.

Authors:  K Kösters; R Nau; A Bossink; I Greiffendorf; M Jentsch; M Ernst; S Thijsen; T Hinks; A Lalvani; C Lange
Journal:  Infection       Date:  2008-01-12       Impact factor: 3.553

10.  Use of a T cell interferon gamma release assay in the investigation for suspected active tuberculosis in a low prevalence area.

Authors:  Niclas Winqvist; Per Björkman; Ann Norén; Håkan Miörner
Journal:  BMC Infect Dis       Date:  2009-07-03       Impact factor: 3.090
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.